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Vaccines against facultative intracellular pathogens are dis-
closed. A host is vaccinated with non-viable but metaboli-
cally active agents. The non-viable agents produce immu-
nogenic components that elicit protective host immune 
responses, with minimal likelihood of host infection by the 
vaccine agent. Living agents, either attenuated or virulent, 
are exposed to a dose of gamma irradiation ( or other strong 
mutagen) that is sufficient to limit or prevent the replication 
of the agents within the host, but that is insufficient to stop 
the metabolic activities of the agent. In vitro exposure of a 
microbial agent to the damaging effects of gamma irradia-
tion or of another strong mutagen induces certain stress 
responses in the infectious agent. These stress responses are 
similar to the stress responses that the virulent agent would 
produce within the tissues of the host. The stress responses 
include the production of antigens that stimulate appropriate 
host immune responses when the irradiated agent is used in 
a vaccine. Examples of facultative intracellular pathogens 
for which non-viable vaccine agents may be made in accor-
dance with the present invention include various bacterial 
pathogens (e.g., Brucella sp., Brucella abortus, Mycobac-
terium sp., Mycobacteriun lepraemurum, Mycobacterium 
tuberculosis, Salmonella sp., Salmonella typhimurium ); 
various mycotic pathogens ( e.g., Blastomyces, Histoplasma, 
Cocidioides); and various protozoa! pathogens (e.g., 
Leishmania, Trypanosomas ). 
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METHOD FOR PROTECTING A 
MAMMALIAN HOST AGAINST INFECTION 
BYBRUCELLA 
2 
Disadvantages of an intracellular habitat (for the 
pathogen) include exposure to a wide variety of potential 
stresses created by the cell, such as altered pH, suboptimal 
nutrient levels, above-optimal temperatures, membrane 
This application is a continuation of application serial 
number 08/705,044, filed Aug. 29, 1996, now abandoned; 
which is a continuation of application Ser. No. 08/148,158, 
filed Nov. 5, 1993, now abandoned. 
5 damaging enzymes and peptides, and reactive free radicals 
that can attack both membranes and DNA 
This invention pertains to a method for protecting a 
mammalian host against infection by Brucella. 
10 
The balance between the advantages of intracellular life 
and its disadvantages determines not only how long an 
intracellular pathogen will survive, but also its ability to 
synthesize virulence factors (factors giving the agent an 
additional advantage and causing disease in the host), as 
well as the severity of the resulting disease. 
Despite the lack of a general understanding of how a host 
develops immunity to intracellular pathogens, several typi-
cal characteristics of efficacious vaccines to these agents 
have been identified. The most effective immunity to such 
agents usually results from infection of the host by the 
virulent agent itself, resulting in clinical or nonclinical 
infection, and full stimulation of an appropriate immune 
response. The most effective immunity to such agents is 
A host generally receives the greatest degree of immunity 
from actual infection by a pathogenic agent. The resulting 
immunity is specific, long-lasting, and complete-but of 
course is useful only if the host survives the disease pro-
duced by the pathogen. The goal of all vaccinations is to 
induce the same degree of solid immunity, but without any 15 
associated risk of disease; in reality few vaccines meet this 
ideal standard. Vaccines are often based either on live 
attenuated pathogenic agents, or on killed agents. The 
degree of protection provided by both types of vaccines is 
highly variable. 20 usually cell-mediated, rather than humoral. Selected sub-
classes of T-lymphocytes that recognize unique antigenic 
determinants in the agent, or that recognize determinants 
associated with the agent, are clonally expanded. Such 
lymphocytes are then able to activate phagocytic white 
A facultative intracellular pathogen is a pathogen that is 
adapted to survive in a host by living within the host's cells, 
but that can also survive outside host cells at least for a time, 
depending on the environment it faces. As a general 
observation, immunity to facultative intracellular pathogens 25 blood cells to kill the intracellular agents. In some instances 
the lymphocytes themselves recognize unique antigens asso-
ciated either with the agent or with a host cell infected with 
the agent, and synthesize and secrete antimicrobial com-
in a vaccinated host is better achieved with a vaccine made 
from living attenuated agents than with a vaccine made from 
killed agents. Immunity results from the survival of the 
living agents within the targeted host tissues for time suffi-
cient to stimulate an appropriate host immune response. See 30 
Davis et al., Microbiology, p. 472 (1967); and P. Nicoletti, 
"Vaccination," Chapter 11 in K. Nielsen et al., Animal 
Brucellosis, pp. 283-299 (1990). An appropriate immune 
response to intracellular pathogens generally depends on the 
activity of T-lymphocytes. Vaccines made from killed agents 
frequently produce only humoral immune responses (i.e., 
antibodies), which are generally less effective in protecting 
the host against subsequent infection by the virulent intra-
cellular pathogen. 
pounds such as perforins. 
Antibodies do not appear to play a large role in protecting 
the host from intracellular pathogens, or in clearing infec-
tions caused by intracellular pathogens. In fact, the antigenic 
structures recognized by antibody-secreting lymphocytes 
may have little in common with the antigenic structures 
35 responsible for effective cell-mediated immune protection. 
Intracellular agents that have been grown on artificial 
growth media (where possible), collected, washed, and 
killed (e.g., by heat or chemical denaturation), and then 
administered to a susceptible host, rarely provide immune 
40 protection against the virulent living agent when the host is 
naturally or experimentally challenged. Agents prepared in 
this manner do result in the production of specific antibodies 
by the "vaccinated" host; however, these antibodies do not 
necessarily confer protection from infection, because the 
The main risk associated with attenuated live vaccines is 
that an attenuated vaccine strain can occasionally infect the 
host and produce disease. Vaccine-induced infection and 
disease can result from at least three different causes: (1) The 
vaccine agent may be insufficiently attenuated. (2) The host 
immune system may be so compromised that it cannot 
eliminate the attenuated agent. (3) The attenuated agent may 
spontaneously revert back to a virulent phenotype. For 
example, it was recently discovered that the genome of the 
attenuated polio-1 virus used in the Sabin polio vaccine is 
identical to the wild-type virulent strain in all but two base 50 
pairs; thus reversion of this attenuated virus to the wild-type 
will occur at a statistically predictable frequency. 
45 pathogens inhabit intracellular sites not typically reached by 
antibodies. 
Even though the medical community recognizes the 
value of the immunity produced by a variety of living 
attenuated vaccines, the risk of infection in the vaccinated 55 
host has limited their use. 
It has been previously demonstrated that exposure of a 
susceptible host to a living, less virulent form of the agent 
can result in long-lived immunity. The resulting immunity 
tends to be cell-mediated, as is the immunity resulting from 
natural infection. The attenuated (nonvirulent) agent must 
generally spend some time within the host before immunity 
develops, colonizing the same cells and tissues of the host as 
does the virulent agent. By contrast, immunity will generally 
be incomplete or absent if the chosen attenuated agent fails 
to survive within host tissues for a long enough period of 
time for a complete immune response to develop, or if the 
attenuated agent parasitizes a different cell type than does 
the virulent agent. 
M. de Bagues et al., "Vaccination with Live Brucella 
abortus RB51 Provides Protection in Mice against Virulent 
B. abortus, B. melitensis, and B. ovis," Abstracts of Papers 
Presented at the 73 rd Annual Meeting of the Conference of 
Research Workers in Animal Diseases, p. 17 (Nov. 9-10, 
Different intracellular pathogens may gain entrance into 
host cells by different mechanisms; they may prefer different 
host cell types; and they may prefer to localize in different 
cellular compartments. Advantages of an intracellular habi- 60 
tat (for the pathogen) include a degree of protection from the 
antimicrobial systems of the host, including protection from 
the host's antibodies, complement, phagocytic white blood 
cells, and cytotoxic non-phagocytic white blood cells. This 
shielding from components of the host immune system 
interferes with the host's ability to mount a specific protec-
tive immune response against the agent. 
65 1992) (which is not prior art to the present application), 
discloses certain Brucella vaccinations, including Brucella 
vaccinations with gamma-irradiated cells. 
US 6,264,952 Bl 
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U.S. Pat. No. 3,449,209 discloses an attenuated live 
Brucella vaccine. U.S. Pat. No. 4,764,370 discloses an 
attenuated live Salmonella vaccine. 
4 
determinants are protective in nature for the Brucella, and 
are not sufficiently expressed until the vaccine organisms 
have interacted with the host. Neither heat-killed nor 
U.S. Pat. Nos. 3,515,708 and 4,340,588 disclose killed 
Brucella vaccines. U.S. Pat. No. 4,687,666 discloses a killed 5 
Leishmania vaccine. 
chemically-killed Strain 19 or Rev 1 strain produces a 
vaccine effective in protecting animals against infection. 
A novel approach to vaccination against facultative intra-
cellular pathogens has been discovered. In the novel method, 
the host is vaccinated with non-viable but metabolically 
U.S. Pat. No. 4,959,211 discloses viral vaccines prepared 
by irradiating the virus. 
U.S. Pat. No. 4,963,354 discloses a vaccine against a 
fibrosarcoma in which the fibrosarcoma cells used in the 10 
active agents. The non-viable agents produce immunogenic 
components that elicit protective host immune responses, 
with minimal likelihood of host infection by the vaccine vaccine were gamma-irradiated at a radiation level that 
ultimately killed the cells, but that left the cells metaboli-
cally viable for a time prior to the cells' death. 
U.S. Pat. No. 5,190,860 discloses mice immunized with 
an irradiated B. abortus strain for the purpose of raising 
monoclonal anti-Brucella antibodies. J. G. Howard et al., 
"Prophylactic Immunization against Experimental 
Leishmaniasis," J. Immunology, vol. 129, pp. 2206-2212 
(1982) reported immunizing mice with gamma-irradiated 
live Leishmania promastigotes. However, the authors 
reported that "irradiated promastigotes do not commend 
themselves as the basis of a vaccine." (At page 2211.) U.S. 
Pat. No. 4,687,666, cited above, reported that the Howard et 
al. irradiated promastigote vaccine did not give satisfactory 
results. (Col. 1, lines 31-45.) 
As one example of the need for improved vaccines 
against facultative intracellular pathogens, Brucellosis is a 
disease affecting livestock and humans throughout the 
world. The disease is caused by five species of the bacterial 
genus Brucella. Humans are typically infected through con-
tact with infected livestock, or by consumption of Brucella 
sp-contaminated food or dairy products. Several live attenu-
ated vaccines have been used to control, although not 
eliminate, Brucella sp infections in animals. Years of 
research have failed to find an effective Brucella whole 
killed vaccine, killed extracted vaccine, or subunit or com-
ponent vaccine. M. Plommet, "Killed Vaccines in Cattle: 
Current Situations and Prospects" in L. G. Adams (Ed.), 
Advances in Brucellosis Research, pp. 215-227 (1990). Live 
attenuated vaccines, by contrast, are usually effective in 
animals, but can occasionally result in infections in vacci-
nated animals, can result in abortions, and may induce 
prolonged serological responses interfering with diagnosis. 
The live attenuated vaccines are virulent to humans, and 
therefore cannot be used in humans. L. G. Adams, "Devel-
opment of Live Brucella Vaccines" in L. G. Adams (Ed.), 
Advances in Brucellosis Research, pp. 250-276 (1990); S. J. 
Revich et al., "Human Infection by Brucella abortus Strain 
19," Can. J. Public Health, vol. 52, pp. 285 ff (1961). There 
agent. 
Living agents, either attenuated or virulent, are exposed 
to a dose of gamma irradiation ( or other strong mutagen) that 
15 is sufficient to limit or prevent the replication of the agents 
within the host, but that is insufficient to stop the metabolic 
activities of the agent. The agents remain metabolically 
active, and are thus able to produce immunogenic com-
pounds capable of stimulating the hosts' protective immune 
20 responses, or to maintain the production of such immuno-
genic compounds. 
In vitro exposure of a microbial agent to the damaging 
effects of gamma irradiation or of another strong mutagen, 
e.g. a radiomimetic chemical, induces certain stress 
25 responses in the infectious agent. These stress responses are 
similar to the stress responses that the virulent agent would 
produce within the tissues of the host. The stress responses 
include the production of antigens that stimulate appropriate 
host immune responses when the irradiated agent is used in 
30 a vaccine. Such vaccination results in host immunity to 
infection by the counterpart virulent agent. 
The host-agent interactions that cause effective immunity 
against an intracellular pathogen are largely unknown. We 
hypothesize (without wishing to be bound by this theory) 
35 that the agent is exposed to a variety of stresses character-
izing an intracellular existence; in response to these stresses, 
the agent synthesizes a number of antigens, such as proteins 
or other molecules that are otherwise unexpressed, or that 
are constitutively expressed in lower concentrations under 
40 non-adverse conditions. These antigens were originally 
described as "heat shock" proteins; however, it is now 
known that stresses other than heat will induce the expres-
sion of many of these proteins. Thus they are now generally 
called "stress response" proteins. Many of these proteins 
45 have been described, and their functions in protection of the 
stressed agent and in immune responses have been docu-
mented. See R. A. Young, "Stress Proteins and 
Immunology," Ann. Rev. Immunology, vol. 8, pp. 401-420 
(1990). 
is no safe and effective vaccine for Brucellosis in humans. 50 The role of stress response proteins in activating the 
J. Kolar, "Brucellosis in Eastern European Countries" in E. 
J. Young et al. (Eds.), Brucellosis: Clinical and Laboratory 
Aspects, pp. 163-172 (1989). 
A common feature of both of the commonly used live 
attenuated Brucella vaccine strains (Brucella abortus strain 
19 and Rev 1 Brucella melitensis) is that they localize and 
survive within the lymphoid tissues of the host for a time, 
much as do their virulent counterparts. Survival of the 
vaccine strains for at least two weeks in these organs is not 
unusual. The vaccine strains stay alive and replicate within 
the cells of the reticuloendothelial system of the lymphoid 
organs. These vaccine strains are usually (but not always) 
eliminated from these tissues by the combined action of 
phagocytic leukocytes, immune T-lymphocytes, and perhaps 
antibodies. The specific antigenic determinants from the live 
attenuated vaccine strains triggering the protective immune 
responses are not known. It is likely that these antigenic 
host's immune system is less well characterized. It is 
hypothesized that the expression of one or more proteins 
induced by a stress response of the agent, or alternatively the 
expression of one or more proteins by an infected host cell, 
55 may stimulate a protective immune response. 
Increased levels of stress response proteins have been 
observed in virus-transformed cells, as well as in 
chemically-induced tumor cells. C. A Finlay et al., "Acti-
vating Mutations for Transformation by p53 Produce a Gene 
60 Product That Forms an hsc70-p53 Complex with an Altered 
Half Life," Mol. Cell. Biol., pp. 531-539 (1988). Stress 
response proteins have been implicated in the recognition 
and rejection of transformed cells. See P. K. Srivastava et al., 
"Tumor Rejection Antigens of Chemically Induced Sarco-
65 mas of Inbred Mice," Proc. Natl. Acad. Sci. USA, vol. 83, 
pp. 3407-3411 (1986); and S. J. Ullrich et al., "A Mouse 
Tumor-Specific Transplantation Antigen is a Heat Shock-
US 6,264,952 Bl 
5 
Related Protein," Proc. Natl. Acad. Sci. USA, vol. 83, pp. 
3121-3125 (1986). 
6 
nity produced by vaccinations with an attenuated living 
agent. A non-viable vaccine has an added advantage over a 
living vaccine in that it cannot cause a vaccine strain 
infection that might result in disease. 
Definition. As used in this specification and in the claims 
below, a "non-viable" agent refers to an organism that is still 
capable of conducting metabolic activities, but that is unable 
to propagate indefinitely in an appropriate environment 
( either in vitro or in vivo). Examples. A boiled suspension of 
The stress response proteins of both eukaryotic and 
prokaryotic cells are highly conserved between species. 
Their synthesis may be induced by a number of host effector 5 
mechanisms, including elevated temperatures, formation of 
toxic free radicals, and deprivation of nutrients. The organ-
isms may also be induced to form stress response proteins by 
exposure to gamma radiation or other strong mutagens. 
Many of the radiation- or mutagen-induced stress response 
proteins are the same as the host-induced stress response 
proteins. 
10 Brucella cells will not respire, and is therefore not consid-
ered to be a "non-viable" agent within this definition; rather, 
it would be considered a killed agent. On the other hand, a 
suspension of cells treated with a high exposure to gamma 
irradiation may retain the ability to conduct metabolic 
15 activities, and thus could be considered a "non-viable" agent 
within this definition, depending on the radiation dose used 
for the particular organism. Depending on the sensitivity of 
the particular organism to the effects of gamma irradiation, 
the cells may undergo several divisions before proliferation 
Mycobacterial stress proteins are immunodominant tar-
gets for both murine antibody and T-lymphocyte immune 
responses. Approximately 20% of mycobacterial-reactive 
CD4+ T-lymphocytes in mice previously immunized with 
Mycobacterium tuberculosis recognize the hsp60 stress pro-
tein of that agent. See R. A. Young, "Stress Proteins and 
Immunology," Ann. Rev. Immunology, vol. 8, pp. 401-420 
(1990); and S. H. E. Kaufmann, "Heat Shock Proteins and 
the Immune Response," Immunology Today, Vol. 11, pp. 
129-136 (1990). It is possible that immune responses to 
these stress proteins may provide a general level of protec-
tion against the earlier events in the infectious process. This 
initial protection would then be reinforced by secondary 25 
immune responses to specific unique antigenic determinants 
20 ceases; such an irradiated organism would still be consid-
ered a "non-viable" agent within this definition, because it 
would be unable to propagate indefinitely. Examples are 
given below of irradiated, non-viable Brucella and other 
non-viable agents. 
Ionizing radiation inactivates bacteria, protozoa, fungi, 
and other pathogens by altering their DNA beyond the 
restorative capacity of the organisms' repair mechanisms. 
By contrast, ribosomal assemblies and RNA are more resis-
tant to ionizing radiation, and may continue to function even 
of the agent. Up-regulation during infection may be an 
important factor in the generally better immunity provided 
by live organisms. See D. Young et al., "Stress-Induced 
Proteins as Antigens in Infectious Diseases" in M. L. Pardue 
et al. (Eds.), Stress-Induced Proteins, pp. 275-85 (1989). 
Free radical formation by host cells is one potential 
source of stress to the agent. Hydroxyl radical formation is 
known to occur as a result of intracellular infection of host 
phagocytic cells. Hydroxyl radicals may damage both the 
host's DNA and the agent's DNA, thereby inducing the 
production of stress response proteins. Radiomimetic agents 
such as bleomycins are known. to result in DNA alteration 
and the expression of stress response proteins by the for-
mation of hydroxyl radicals. 
We hypothesize (without wishing to be bound by this 
theory) that the exposure of intracellular pathogens to 
gamma irradiation (or other strong mutagens) produces free 
radicals that alter the agent's DNA The altered DNA 
invokes the protective stress response, accompanied by the 
production of stress response proteins. The stress-related 
proteins induced by irradiation are thought to simulate the 
stress response proteins produced by the agent when it is 
exposed to host-origin antimicrobial compounds. The stress 
response proteins, regardless of how generated, can then 
stimulate a protective immune response in a vaccinated host. 
Alternatively, we hypothesize (without wishing to be 
bound by this theory) that the exposure of intracellular 
pathogens to gamma irradiation (or other strong mutagens) 
causes expression of at least one pathogen stress protein or 
other pathogen-synthesized molecule at a level of expression 
substantially greater than the level of constitutive expression 
by the pathogen under non-adverse conditions, and that this 
pathogen stress protein or other pathogen-synthesized mol-
ecule is one that can, in turn, cause a host cell to express a 
host stress protein or other host-cell-synthesized molecule 
signalling to the host's immune system that the cell is 
infected by a pathogen. Then this host-cell-synthesized 
molecule stimulates a protective immune response. 
For this reason an irradiated non-viable agent can induce 
protective immunity whose effectiveness exceeds that pro-
duced by conventionally killed agents, and rivals the immu-
30 when the DNA has been damaged beyond repair. B. A 
Bridges, "Bacterial Reaction to Radiation," in J. G. Cook 
(Ed.), Patterns of Progress, Microbiology Series, pp. 72 ff 
(1976). Thus exposure of the agents to an appropriate dose 
of gamma radiation (or other mutagen) will prevent their 
35 propagation, without preventing their synthesis of some or 
all of the following: stress related proteins, invasion 
proteins, and inhibitors of phagocytosis. See generally F. C. 
Neidhardt et al., "The Genetics and Regulation of Heat 
Shock Proteins," Ann. Rev. Genet., vol. 18, pp. 295-329 
40 (1984); B. B. Finlay et al., "Salmonella: A Model to Study 
Intracellular Parasitism" in L. G. Adams (Ed.), Advances in 
Brucellosis Research, pp. 111-118 (1990); and S. J. Brett et 
al. , "Interactions of Mycobacterium lepraemurium with 
Resident Peritoneal Macrophages; Phagocytosis and Stimu-
45 lation of the Oxidative Burst," C.lin. Exp. Immunol., vol. 71, 
pp. 32-38 (1988). Thus when such an irradiated agent is 
used as a vaccine, the host immune system can develop an 
immune response to some or all of these potential immu-
nogens. By contrast, heat-killed bacteria do not produce as 
50 many of these proteins, and those that are produced may not 
be expressed in the same quantities. 
Appropriate doses of gamma irradiation or other strong 
mutagens may be used to prevent the further replication of 
the facultative intracellular agents, while still allowing these 
55 organisms to synthesize biologically active molecules that 
aid their survival within host cells, and that stimulate the 
host's protective immune response. Examples of facultative 
intracellular pathogens for which non-viable vaccine agents 
may be made in accordance with the present invention 
60 include various bacterial pathogens (e.g., Brucella sp., Bru-
cella abortus, Brucella melitensis, Mycobacterium sp., 
Mycobacterium lepraemurum, Mycobacterium tuberculosis, 
Salmonella sp., Salmonella typhimurium, Listeria, Shigella 
flexneri, Rickettsia tsutsugamushi, Rickettsia prowazekii, 
65 Rickettsia rickettsii, Chlamydia psittaci, Chlamydia 
trachomatis, Chlamydia pneumoniae, Coxiella burnettii, 
Yersinia sp., Yersinia pestis, Legionella pneumonophia, 
US 6,264,952 Bl 
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Francisella); various mycotic pathogens (e.g., Blastomyces 
sp., Blastomyces dermatitides, Histoplasma sp., Histo-
plasma capsulatum, Coccidioides, Cryptococcus 
neoformans); and various protozoa! pathogens (e.g., Leish-
mania donovani, Leishmania mexicani, Trypanosoma sp., 5 
Trypanosoma cruzi, Toxoplasma sp., Toxoplasma gondi, 
Plasmodium, Babesia, Theileria, Isospora, and Eimeria). 
8 
was scraped from the solid agar and suspended in 30 ml of 
tryptose broth to give a concentration of at least 1.0xl010 
viable bacteria per ml. This suspension of bacteria, placed in 
a 100 ml screw cap bottle, was immediately subjected to 
Cobalt-60 irradiation at 2.2 Krads/min for 495 minutes, for 
a total irradiation of 1.089 Mrads. One hundred µl of the 
irradiated bacterial suspension was directly plated onto 
tryptose agar and cultured for one week at 37° C. in 7% CO2 
to verify that the bacteria were unable to replicate, and were 
therefore "non viable." (This step ran for a time sufficient to 
have identified even a single bacterium capable of unre-
strained replication, had there been such a bacterium in the 
original irradiated suspension.) The remainder of the sus-
pension of irradiated bacteria was divided into 26, 1 ml 
Determining an appropriate dose of radiation or other 
mutagen to use with a particular organism will be within the 
ability of one of ordinary skill in the art who is given the 
10 
teachings of the present specification. The dose used will be 
one that is high enough to prevent the further replication of 
the organism, while still allowing the organism to metabo-
lize. Such a dose can readily be identified by attempting to 
grow the organism in a suitable medium after irradiation or 
other mutagenic treatment. 
Strong mutagens other than radiation can be used in the 
practice of this invention; in particular, radiomimetic agents 
such as bleomycins, etoposide, and teniposide can also 
mimic the stress that the intracellular environment places on 
intracellular pathogens, and can cause the production of 20 
many of the same protective antigens by the organisms. 
(Bleomycins, for example, are cytotoxic glycopeptide anti-
biotics isolated from strains of Streptomyces verticillus. One 
bleomycin is sold under the trademark Blenoxane® by 
Bristol Laboratories, Syracuse, N.Y.) 
15 freezer vials, which were flash frozen in liquid nitrogen. The 
frozen bacterial suspensions were stored at - 70° C. until 
used. Selected vials were determined to contain approxi-
mately 2.0xl011 bacteria per vial (based on dry weight). 
25 
After thawing, irradiated bacterial suspensions were centri-
fuged and washed in physiological saline. Washed bacteria 
were resuspended in physiological saline and used in the 
immunizations described below. 
Examples 3-7 
Because relatively few organisms naturally survive 
within the host's cells to produce the protective antigens-
generally as few as 100 to 1000 bacteria per gram of 
lymphoid tissue-irradiation of stock cultures in excess of 
1011 to 1013 CPU's (colony-forming units) will produce 
considerably larger amounts of the desired immunogens. 30 
Furthermore, some organisms evade host defense systems 
Female BALB/c mice approximately 10 weeks of age 
were randomly divided into 5 treatment groups of 5 mice 
each. Group 1 mice were inoculated intraperitoneally with 
live B. abortus strain RB51 at a dose of 3.0xl08 CFU, with 
no adjuvant. Group 2 mice were inoculated intraperitoneally 
with 20 µg dry weight (approximately 1.0xl09 CFU) 
methanol-killed B. abortus strain RB51, mixed with a com-
mercial adjuvant (QS-21) (Cambridge BioScience, 
Cambridge, Mass.). Group 3 mice were inoculated intrap-
eritoneally with the equivalent of 20 µg dry weight of the 
gamma-irradiated B. abortus strain RB51 (approximately 
1.0xl09 CFU), with the QS-21 Adjuvant. Group 4 mice were 
inoculated subcutaneously with 5.0xl04 CFU of living B. 
abortus strain 19 with no adjuvant. Group 5 (the control) 
received an intraperitoneal inoculation of phosphate-
buffered saline. 
by changing the antigens presented on their cell surface. For 
this reason, and because it is not generally known how many 
varieties of protective antigens are produced by a particular 
pathogen, the probability of the production of all potential 35 
immunogens is much greater when large numbers of organ-
isms are simultaneously exposed to the stress of gamma 
radiation or other strong mutagen. Thus it is believed that 
immunity to a broad spectrum of possible immunogens is 
induced by vaccines in accordance with the present inven- 40 
tion. This is a distinct advantage of the present invention, as All groups were given inoculations on Day O of the study. 
On Day 28, groups 2 and 3 were reinoculated as described 
above. On Day 35, all five groups were inoculated intrave-
nously with 5.0xl04 CFU of living B. abortus strain 2308 
it reduces a pathogen's ability to evade host immune sys-
tems by repeatedly altering surface antigens, a defense 
mechanism employed by some pathogens. 
EXAMPLES 
Example 1 
Gamma-irradiated Brucella abortus preparations were 
observed to be superior to preparations of heat-killed B. 
abortus in stimulating the in vitro proliferation of immune 
bovine T-lymphocyte cell lines. The irradiated bacteria syn-
thesized at least eight proteins that were not produced by the 
heat-killed B. abortus. The irradiated organism also synthe-
sized greater quantities of at least five protein bands that 
were shared with the heat-killed bacteria. Thus the gamma-
irradiated B. abortus provided in vitro antigenic stimuli that 
were deficient in the heat-killed cells. For additional details, 
see J.H. Wyckoff et al., "Comparison of Brucella abortus 
Antigen Preparations for in vitro Stimulation of Immune 
Bovine T-Lymphocyte Cell Lines," Vet. Immunol. 
Immunopathol., vol. 36, pp. 45-64 (1993) (not prior art to 
this application), the entire disclosure of which is incorpo-
rated by reference. 
Example 2 
Brucella abortus strain RB51 was cultured on tryptose 
agar at 37° C. in 7.0% CO2 for 72 hours. The bacterial lawn 
45 (the virulent B. abortus challenge strain). On Day 42, all 
mice were killed, and their spleens were removed and 
cultured to determine the number of virulent B. abortus 
challenge strain organisms colonizing the organ. 
Mice in Group 5 (the control group) had a mean log 6.6 
50 B. abortus per spleen (i.e., 106 ·6 bacteria per spleen). Group 
1 mice (those receiving live RB51) had a mean log 0.91 
reduction of challenge strain B. abortus versus the control 
group. Group 2 mice (those receiving the killed RB51 with 
adjuvant) had a mean log 0.1 reduction in challenge bacteria 
55 per spleen. Group 3 mice (those receiving the gamma-
irradiated B. abortus and adjuvant) had a mean log 0.43 
reduction in challenge bacteria per spleen. The group 4 mice 
(those receiving live strain 19 B. abortus) had a mean log 
2.12 reduction in the number of challenge bacteria per 
60 spleen. 
The reduction of colonization of the spleen with the 
challenge bacteria was significant at P~0.001 for group 1, at 
P~0.05 for group 3, and at P~0.001 for group 4. There was 
no significant reduction in colonization of spleen with the 
65 challenge strain of bacteria in group 2 as compared to 
control group 5. The adjuvant QS-21 alone conferred no 
protection to challenged mice (data not shown). 
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Note that while Group 3 showed a significant reduction 
compared to control, that Group did not show as much 
reduction as Groups 1 and 4. However, Group 3 still 
exhibited serviceable immunity, with a vaccine that is safer 
to the host than are the live vaccines of Groups 1 and 4. 
Example 8 
It was demonstrated that the transfer of purified popula-
tions of T-lymphocytes recovered from each of the above 
Groups 1, 3, and 4 conferred significant levels of protection 
to recipient naive mice challenged with B. abortus strain 
2308 (data not shown). 
In mice, antibodies and T-cells work together to limit 
challenge infections with strain 2308. By contrast, neither 
mice immunized with live RB51 nor mice immunized with 
irradiated RB51 produce antibodies that aid in eliminating 
the challenge strain. The immunity conferred by both types 
of RB51 vaccines appear to be wholly due to cell-mediated 
immunity. The usefulness of antibodies in eliminating bru-
cellosis ( other than in mice) is thought to be limited. 
5 
10 
These vaccines will be used to immunize mice, cattle, and 
humans against Brucella as otherwise described above. 
Examples 14-42 
Following the teachings of this specification, and making 
such appropriate modifications in the culturing and vacci-
nation techniques described above as will occur to those of 
ordinary skill in the art who are given those teachings, 
vaccines will be made against the following facultative 
10 intracellular pathogens: Brucella melitensis, Mycobacterium 
lepraemurum, Mycobacterium tuberculosis, Salmonella 
typhimurium, Listeria, Shigella flexneri, Rickettsia 
tsutsugamushi, Rickettsia prowazekii, Rickettsia rickettsii, 
Chlamydia psittaci, Chlamydia trachomatis, Chlamydia 
15 pneumoniae, Coxiella burnettii, Yersinia pestis, Legionella 
pneumonophia, Francisella, Blastomyces dermatitides, His-
toplasma capsulatum, Coccidioides, Cryptococcus 
neoformans, Leishmania donovani, Leishmania mexicani, 
Trypanosoma cruzi, Toxoplasma gondi, Plasmodium, 
20 Babesia, Theileria, Isospora, and Eimeria. These vaccines 
will be used to vaccinate suitable hosts against the corre-
sponding virulent pathogens. These data demonstrated that significant protection 
against challenge infection was achieved with gamma-
irradiated B. abortus strain RB51. Further, the study dem-
onstrated that cell-mediated immune responses to the 25 
gamma-irradiated vaccine were effective in conferring pro-
tection. 
The entire disclosures of all references cited in this 
specification are hereby incorporated by reference. Also 
incorporated by reference is the entire disclosure of U.S. 
patent application Ser. No. 08/148,158, filed Nov. 5, 1993. 
We claim: 
Example 9 
The non-viable Brucella vaccine described above will be 30 
used to immunize cattle against Brucellosis. 
1. A method for immunizing a mammalian host against 
infection by Brucella, comprising administering to the mam-
malian host a protective amount of a Brucella strain that has 
been subjected to an amount of ionizing radiation that is 
sufficient to make the strain non-viable. 
Example 10 
Because the gamma-irradiated Brucella vaccine will not 
cause infection, it is expected that this vaccine can be used 
in humans, which would make this the first effective Bru-
cella vaccine suitable for use in humans. The active portion 
of the vaccine will be the irradiated Brucella strain described 
2. A method as recited in claim 1, wherein the Brucella 
strain is administered to the mammalian host in conjunction 
35 with a pharmaceutically acceptable carrier. 
above, and this active portion will be administered in a 40 
pharmaceutically acceptable carrier. 
Examples 11-13 
Brucella vaccines otherwise as described above will be 
made, except that bleomycin, etoposide, or teniposide will 45 
be used as the mutagen in lieu of the gamma irradiation. 
3. A method as recited in claim 1, wherein said irradiated 
strain comprises Brucella abortus. 
4. A method as recited in claim 3, wherein the Brucella 
strain is administered to the mammalian host in conjunction 
with a pharmaceutically acceptable carrier. 
5. A method as recited in claim 1, wherein said irradiated 
strain comprises Brucella melitensis. 
6. A method as recited in claim 5, wherein the Brucella 
strain is administered to the mammalian host in conjunction 
with a pharmaceutically acceptable carrier. 
* * * * * 
